Ordering The
Cunningham Panel™
We deliver next-generation antibody tests that detect whether an infection or autoimmune reaction could be causing neurologic or psychiatric symptoms.

Prescribers: Ordering The Cunningham Panel™

The Cunningham Panel™ of tests requires a clinician order before we can receive and process any specimen. Moleculera Labs can accept clinician test orders from all 50 states in the U.S.

Steps to Order The Cunningham Panel™

  1. Prescriber Portal

    We have a secure Prescriber Portal for clinicians practicing in the U.S. The portal allows practitioners to order tests and retrieve and review results.

    Create a profile in the Prescriber Portal.

    Place an order for the Cunningham Panel™ and submit the patient’s information.

  2. Specimen Collection Supplies

    We will send specimen collection supplies by express shipping to the patient address provided, which may require about 2-3 business days to arrive, depending on the patient’s location.

    Clinicians who will perform the blood collection at their facility may order specimen collection supplies through the online portal or by calling us at (405) 239-5250.

  3. Specimen Collection

    The patient will need to have blood collected at your site or an alternate phlebotomy location. IMPORTANT: Blood must be collected into the two glass red-top tubes provided, the serum separated and transferred to the serum transfer tube provided. The Red Top Glass tubes (provided) are the only validated tubes for this panel. Blood collected in any other tubes must be rejected. In cases where the blood cannot be centrifuged, whole blood can be accepted (refer to the Specimen Collection Instructions included with the collection supplies for details).

  4. Specimen Return

    The serum sample and the completed patient forms (provided in the specimen collection supplies) must be sent to Moleculera Labs overnight (shipping label provided, and shipping costs covered by Moleculera).


  • SPECIMENS MUST ARRIVE ON A MOLECULERA BUSINESS DAY. Our facility is closed and unable to receive specimens on weekends and holidays.
  • The ice packs provided with the specimen collection supplies must be frozen for a minimum of 24 hours prior to shipping.
  • Specimens that arrive warm will be rejected.

Patient results are uploaded to our secure Prescriber Portal and you will be notified by e-mail when results are available.  Due to the complexity and number of tests, our turn-around-time may vary. Please click here for our current turn-around-time.  Click here to log-in to the Prescriber Portal and order the Cunningham Panel™.

Moleculera can also accept orders written on a prescription form. Prescription form orders must include the following information:

  • Provider name, address, phone/fax number, email (for results) and NPI.
  • Patient full name, sex assigned at birth and date of birth.
  • Responsible party name, email address, and phone number.
  • ICD-10 Diagnosis code/codes

Practitioners in New York, please note:

Under New York regulations, practitioners in New York State may order the Cunningham Panel™ for their patients, but specimens must be collected at a facility outside the State of New York. At this time, Moleculera Labs is not licensed in the State of New York and as a result is unable to accept specimens collected in New York. 

Pricing and Reimbursement

The total cost of the test is $995. The patient is ultimately responsible for the full cost of the test. For patients with commercial (private or employer group) insurance, a deposit of $495 is required. Moleculera will file a claim to the patient’s insurance carrier as a courtesy. Patients on government-sponsored plans such as Medicaid, TriCare, and Medicare, must pay in full. Moleculera is unable to file claims to any government funded programs. Payment arrangements are available on a case-by-case basis and the patient can contact our office for assistance.

Download The Cunningham Panel Guide For Clinicians
Infections may result in developing OCD
Can you develop neuropsychiatric symptoms from an infection?

Learn more about how infections can trigger neuropsychiatric symptoms

Cunningham Panel helps identify an autoimmune disorder in child initially diagnosed with schizophrenia

Cunningham Panel™ helps identify an autoimmune disorder in child initially diagnosed with schizophrenia

Researchers describe a complex case involving a 15-year-old girl, who abruptly developed multiple neurologic and psychiatric symptoms.

Autoimmune diseases and severe infections as risk factors for mood disorders: a nationwide study

Autoimmune diseases and severe infections as risk factors for mood disorders: a nationwide study

This nationwide, population-based, prospective cohort study examines the link between mood disorders, infections, and autoimmune disease.

Cunningham Panel predicts IVIG treatment response in autistic patients with autoimmune encephalopathy

Cunningham Panel™ predicts IVIG treatment response in autistic patients with autoimmune encephalopathy

Case series examines the link between autism spectrum disorders, immune dysfunction, and treatment response to IVIG. 

B. Robert Mozayeni, MD

Medical and Clinical Advisor

B. Robert Mozayeni MD

Dr. B. Robert Mozayeni was trained in Internal Medicine and Rheumatology at Yale and at NIH. He has had pre- and post-doctoral Fellowships in Molecular Biophysics and Biochemistry at Yale, and also at NIH where he was a Howard Hughes Research Scholar at LMB/DCBD/NCI and later, Senior Staff Fellow at LMMB/NHLBI/NIH. Editorial board of Infectious Diseases – Surveillance, Prevention and Treatment. Past President of the International Lyme and Associated Diseases Society (ILADS).

He is an expert in Translational Medicine, the science and art of advancing medical science safely and efficiently. He is a Fellow of the non-profit Think Lead Innovate Foundation and is a co-founder of the Foundation for the Study of Inflammatory Diseases. He is a Founder of the Foundation for the Study of Inflammatory Diseases to crowd-source medical solutions for complex conditions using existing knowledge, diagnostic methods, and therapies to meet patient needs immediately. He is the Chief Medical Officer of Galaxy Diagnostics, LLC. He is a Board member of the Human-Kind Alliance. Dr. Mozayeni has held admitting privileges (since 1994) on the clinical staff of Suburban Hospital, a member of Johns Hopkins Medicine and an affiliate of the National Institutes of Health Clinical Center.

Safedin Sajo Beqaj, PhD, HCLD, CC (ABB)

Moleculera Labs, Clinical Laboratory Advisor
Medical Database, Inc., President and CEO

Sajo Baqaj, PhD

Dr. Sajo Beqaj is board certified in molecular pathology and genetics and licensed as a Bioanalyst and High Complexity Laboratory Director. He has been practicing as a laboratory director since 2005.

Dr. Beqaj served as a technical director and was part of the initial management team for several well-known laboratories in the clinical lab industry including PathGroup, Nashville, TN; DCL Medical Laboratories, Indianapolis, IN, and Pathology, Inc, Torrance, CA. He is currently serving as off-side CLIA laboratory director for BioCorp Clinical Laboratory, Whittier, CA and Health360 Labs, Garden Grove, CA.

Dr. Beqaj received his Ph.D. in Pathology from Wayne State University Medical School, Detroit, Michigan. He performed his post-doctoral fellowship at Abbott Laboratories from 2001-2003 and with Children’s Hospital and Northwestern University from 2003-2005.

Dr. Beqaj has taught in several academic institutions and has published numerous medical textbook chapters and journal articles. He has served as a principal investigator in clinical trials for several well-known pharmaceutical and diagnostic companies such as Roche HPV Athena, Merck HPV vaccine, BD vaginitis panel, Roche (Vantana) CINtec® Histology clinical trials, and has presented various scientific clinical abstracts and presentations.

He is a member of several medical and scientific associations including the Association of Molecular Pathology, American Association of Clinical Chemistry and the Pan Am Society for Clinical Virology. He has served on a number of clinical laboratory regulatory and scientific committees, and has assisted several laboratories and physicians as a Clinical Laboratory Consultant.

Rodney Cotton, MBA

Moleculera Labs Board Member

Rodney Cotton, MBA

Rodney Cotton, MBA is an entrepreneurial thought leader in the pharmaceutical/biotech industry who is known for his holistic perspective, bias for action in the face of challenges, and commitment to agile processes.

Rod is an independent director for Orchard Software, a private equity-backed health technology company owned by Francisco Partners; an advisory board member to Flo2 Ventures, a venture capital-backed healthcare and health equity accelerator; and a member of the board of directors and three board committees (Audit, Compliance & Finance; Governance & Equity; and Quality of Care) for Community Health Network.

He built a successful career at Roche spanning more than two decades and culminating in the role of SVP, Head of Strategy & Transformation, and Chief of Staff to the CEO for Roche Diagnostics, the North American headquarters of the world’s largest ($17B) diagnostics company.

While at Roche, Rod led key enterprise initiatives, such as milestone corporate communications, health equity coalitions, the US/Roche Group audit, and global/US acquisition integrations. With 40+ years of experience, he drove the financial turnaround and cultural transformation of four global healthcare companies, led teams of up to 280 total reports, managed P&L of more than $1 billion, and served as a key member of the senior leadership team executing the most significant restructuring of the company in two decades.

In the face of the COVID-19 pandemic, Rod and his team at Roche accelerated six ground breaking products in 11 months, including the first launch of the market’s most accurate and in demand molecular diagnostic test. He also solved extraordinary challenges of product scarcity, supply chain, product allocation, and logistics to achieve accelerated global sourcing and self manufacturing in line with testing guidelines.

A frequent public speaker on health equity and other topics, Rod was named one of the Most Influential Black Executives in Corporate America by Savoy Magazine and one of the Top Blacks in Healthcare by BlackDoctor.org. He also received The Sagamore of the Wabash Award, one of the highest Indiana State honors, bestowed by Indiana Governor Eric J. Holcomb.

Rod holds an M.B.A. from California State University, Dominguez Hills, an M.S. in Strategic Management from the University of Southern California, and a B.A. in Biological Sciences & Technology from the University of California at Santa Barbara.